CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Launched by CARIBOU BIOSCIENCES, INC. · Nov 16, 2020

Keywords

ClinConnect Summary

The ANTLER clinical trial is studying a new treatment called CB010A for adults with a type of blood cancer known as relapsed or refractory B-cell non-Hodgkin lymphoma. This means the lymphoma has either come back after treatment or has not responded well to previous therapies. The trial aims to find out how safe this new treatment is, how well it works, and how the body processes it after receiving it. Participants will first undergo a procedure to prepare their bodies for the treatment, which includes using other medications to help improve the effectiveness of the new therapy.

To be eligible for this trial, participants must be at least 18 years old and have a documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after standard treatments. They should also be in relatively good health, meaning they should be able to perform daily activities without much difficulty. However, there are some conditions that would exclude someone from participating, such as having had certain previous treatments or other serious health issues. If chosen for the trial, participants can expect to be closely monitored for their health and wellbeing throughout the study. This trial is currently recruiting, and all genders are welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age greater than or equal to 18 at the time of enrollment
• • Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
• • Eastern Cooperative Oncology Group performance status 0 or 1
• • Adequate hematologic, renal, liver, cardiac and pulmonary organ function
• Exclusion Criteria:
• • Prior therapy with an anti-CD19 targeting agent
• • Active or chronic graft versus host disease requiring therapy
• • Prior allogeneic stem cell transplantation
• • Central nervous system (CNS) lymphoma, prior CNS malignancy
• • Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.
• • Primary immunodeficiency
• • Current or expected need for systemic corticosteroid therapy
• • Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
• • Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
• • Unwillingness to follow extended safety monitoring